Literature DB >> 20461479

Proven efficacy of combined androgen depletion therapy.

Hideyuki Akaza1.   

Abstract

Year:  2010        PMID： 20461479     DOI： 10.1007/s11934-010-0117-5

Source DB:  PubMed          Journal:  Curr Urol Rep        ISSN： 1527-2737            Impact factor:   3.092


× No keyword cloud information.
  6 in total

Review 1.  A re-assessment of the role of combined androgen blockade for advanced prostate cancer.

Authors:  L Klotz; P Schellhammer; K Carroll
Journal:  BJU Int       Date:  2004-06       Impact factor: 5.588

2.  Twenty years of controversy surrounding combined androgen blockade for advanced prostate cancer.

Authors:  Judd W Moul
Journal:  Cancer       Date:  2009-08-01       Impact factor: 6.860

3.  Bicalutamide 80 mg combined with a luteinizing hormone-releasing hormone agonist (LHRH-A) versus LHRH-A monotherapy in advanced prostate cancer: findings from a phase III randomized, double-blind, multicenter trial in Japanese patients.

Authors:  M Usami; H Akaza; Y Arai; Y Hirano; S Kagawa; H Kanetake; S Naito; Y Sumiyoshi; Y Takimoto; A Terai; H Yoshida; Y Ohashi
Journal:  Prostate Cancer Prostatic Dis       Date:  2007-01-02       Impact factor: 5.554

4.  Risk assessment among prostate cancer patients receiving primary androgen deprivation therapy.

Authors:  Matthew R Cooperberg; Shiro Hinotsu; Mikio Namiki; Kazuto Ito; Jeanette Broering; Peter R Carroll; Hideyuki Akaza
Journal:  J Clin Oncol       Date:  2009-08-10       Impact factor: 44.544

Review 5.  Initial hormonal management of androgen-sensitive metastatic, recurrent, or progressive prostate cancer: 2006 update of an American Society of Clinical Oncology practice guideline.

Authors:  D Andrew Loblaw; Katherine S Virgo; Robert Nam; Mark R Somerfield; Edgar Ben-Josef; David S Mendelson; Richard Middleton; Stewart A Sharp; Thomas J Smith; James Talcott; Maryellen Taplin; Nicholas J Vogelzang; James L Wade; Charles L Bennett; Howard I Scher
Journal:  J Clin Oncol       Date:  2007-04-02       Impact factor: 44.544

6.  Superior anti-tumor efficacy of bicalutamide 80 mg in combination with a luteinizing hormone-releasing hormone (LHRH) agonist versus LHRH agonist monotherapy as first-line treatment for advanced prostate cancer: interim results of a randomized study in Japanese patients.

Authors:  Hideyuki Akaza; Akito Yamaguchi; Tadashi Matsuda; Mikio Igawa; Hiromi Kumon; Asaki Soeda; Yoichi Arai; Michiyuki Usami; Seiji Naito; Hiroshi Kanetake; Yasuo Ohashi
Journal:  Jpn J Clin Oncol       Date:  2004-01       Impact factor: 3.019
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.